Vincent Lo Re III, MD, MSCE
| Office Location | 836, Blockley Hall |
| Office Phone | 215-573-5964 |
| vincentl@mail.med.upenn.edu | |
Faculty Information | |
| CCEB Appointment | Senior Scholar, Epidemiology |
| Primary Faculty Appointment | Assistant Professor of Medicine, Division of Infectious Diseases, University of Pennsylvania Perelman SOM |
| DBE Appointment | Assistant Professor of Epidemiology |
Research Statement
Dr. Lo Re is an Infectious Diseases physician and clinical epidemiologist whose area of interest is HIV-viral hepatitis coinfection. Dr. Lo Re’s research has focused on the clinical outcomes of chronic viral hepatitis infection and its treatment in the HIV population. Recently, he has examined the incidence and risks factors for weight loss during HIV/hepatitis C therapy. He is currently examining novel risk factors for end-stage liver disease among HIV/hepatitis-coinfected patients in two national HIV cohorts – the Veterans Aging Cohort Study and the Women’s Interagency HIV Study. Another aim of this grant is to develop and internally validate a clinical predictive index to stratify HIV/hepatitis C-coinfected patients according to their risk of progression to hepatic decompensation.
Dr. Lo Re has also conducted research examining adherence to pegylated interferon and ribavirin hepatitis C therapy, specifically examining the levels of adherence required for maximal hepatitis C suppression and risk factors for poor adherence to these therapies.
Dr. Lo Re is also interested in HIV/hepatitis B virus coinfection. Recent work in this area has focused on the prevalence, risk factors, and clinical significance of occult hepatitis B virus infection in HIV-infected patients.
Dr. Lo Re is also interested in epidemiologic methods research, particularly examining optimal methods to ascertain viral hepatitis-associated clinical outcomes in ongoing cohort studies.
Selected Publications
Lo Re V III, Frank I, Gross R, Synnestvedt M, Localio AR, Kostman JR, Strom BL. Validity of self-reported hepatitis B and C virus infections among HIV-infected patients. J Clin Epidemiol 2007; 60: 294-9.
Lo Re V III, Frank I, Gross R, Dockter J, Linnen JM, Giachetti C, Tebas P, Synnestvedt M, Localio AR, Kostman JR, Strom BL. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44: 315-20.
Lo Re V III, Kostman JR, Gross R, Reddy KR, Mounzer K, Zemel BS, Rennert H, Stieritz DD, Putt M, Frank I, Strom BL. Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy. J Acquir Immune Defic Syndr 2007; 44: 344-50.
Lo Re V III, Wertheimer B, Localio AR, Kostman J, Dockter J, Linnen J, Giachetti C, Tebas P, Frank I, Strom BL, Gross R. No increased incidence of transaminitis among HIV patients with occult hepatitis B. J Clin Virol. In Press.
Lo Re V III, Amorosa VK, Localio R, O'Flynn R, Teal V, Dorey-Stein Z, Kostman JR, Gross R. Adherence to hepatitis C virus therapy and early virologic outcomes. In Submission.
